Autor según el artículo: Arellano-Orden E; Romero-Romero B; Sánchez-López V; Martín-Juan J; Rodríguez-Panadero F; Otero-Candelera R
Departamento: Medicina i Cirurgia
Autor/es de la URV: Porras Ledantes, Jose Antonio
Palabras clave: Talc pleurodesis Survivin Survival Pleurodesis Metaanalysis Mesothelioma cells Malignant pleural effusion Lung-cancer Induction Expression Diagnostic-value Bcl-2 Apoptosis survival pleurodesis malignant pleural effusion
Resumen: © 2018 Stichting European Society for Clinical Investigation Journal Foundation Background: Survivin is a well-known member of the inhibitor of apoptosis family, and has been related to increased tumour aggressivity, both in tissue and in pleural fluid. Objectives: In patients with malignant pleural effusion, we sought to investigate the changes in pleural fluid survivin concentrations induced by talc instillation into the pleural space. Those changes were also examined in relation to pleurodesis outcome and patient survival. Methods: We investigated 84 patients with malignant pleural effusion who underwent talc pleurodesis. Of them, 32 had breast cancer, 25 lung cancer and 27 had mesothelioma. Serial samples of pleural fluid were obtained before thoracoscopy (baseline) and 24 hours thereafter. Results: Survivin levels were successfully quantified in all pleural fluid samples, and they were significantly higher in samples obtained after thoracoscopic talc poudrage compared with baseline (P <.001). Patients with higher pleural fluid survivin levels at baseline had a significantly poorer pleurodesis outcome (P =.004). A 30 pg/mL cut-off for baseline survivin in pleural fluid predicted failure of pleurodesis with a 54% sensitivity and 79% specificity (P =.009). Moreover, median postpleurodesis survival of patients with baseline survivin levels ≥30 pg/mL was 4 months (range: 0.1-38), compared with 13 months (range: 0.1-259) in patients below that cut-off (P <.001). Conclusion: Elevated pleural fluid survivin concentrations are useful to predict failure of pleurodesis and are associated with shorter survival in patients with malignant pleural effusion.
Áreas temáticas: Saúde coletiva Odontología Nutrição Medicine, research & experimental Medicine, general & internal Medicine (miscellaneous) Medicina ii Medicina i Interdisciplinar General medicine Farmacia Educação física Clinical biochemistry Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología Biochemistry
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 00142972
Direcció de correo del autor: joseantonio.porras@urv.cat
Identificador del autor: 0000-0001-6418-1822
Fecha de alta del registro: 2024-09-07
Versión del articulo depositado: info:eu-repo/semantics/acceptedVersion
Enlace a la fuente original: https://onlinelibrary.wiley.com/doi/abs/10.1111/eci.12895
URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
Referencia al articulo segun fuente origial: European Journal Of Clinical Investigation. 48 (4):
Referencia de l'ítem segons les normes APA: Arellano-Orden E; Romero-Romero B; Sánchez-López V; Martín-Juan J; Rodríguez-Panadero F; Otero-Candelera R (2018). Survivin is a negative prognostic factor in malignant pleural effusion. European Journal Of Clinical Investigation, 48(4), -. DOI: 10.1111/eci.12895
DOI del artículo: 10.1111/eci.12895
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2018
Tipo de publicación: Journal Publications